Free-text search
Articles per year:
Content Types
-
SciLifeLab set for major expansion in Stockholm
SciLifeLab is expanding its operations at Campus Solna by more than 9,000 square metres. Akademiska Hus is investing around SEK 230 million in the redevelopment, which will provide the research centre with additional laboratory space.
-
ResoTher eyes pharma deal as heart attack candidate moves forward
ResoTher Pharma is taking its lead candidate RTP-026 into a larger international study after seeing encouraging efficacy signals in patients with severe heart attacks. The Danish biotech hopes the next readout will bring it closer to a major pharma partnership.
-
After Phase III setback – Diamyd sees effect in long-term follow-up
Following its major Phase III setback earlier this year, Diamyd Medical is reporting new positive data. A long-term follow-up of an older study suggests that retogatein may delay progression to insulin-requiring type 1 diabetes in a genetically defined group of children.
-
Janne Backman takes over as chair of IRLAB
IRLAB Therapeutics has appointed a new board chair. Janne Backman succeeds Carola Lemne, who is stepping down after eight years on the research company’s board.
-
Saline recalled after potentially dangerous mix-up
A batch of potentially mislabelled IV infusion bags is being recalled in the US by Otsuka ICU Medical. The company is warning that accidental injection of the product could have potentially fatal consequences.
-
Swedish biotech signs blockbuster deal with Novo – ”It’s Nanexa 2.0”
Nanexa has signed a global licensing deal with Danish pharmaceutical giant Novo in an agreement that could be worth up to SEK 13 billion.
-
Lundbeck relocates US headquarters and establishes innovation hub in Boston
Danish pharmaceutical company Lundbeck is relocating its US headquarters from Deerfield, Illinois, to the Boston region, where the company is also establishing a global innovation hub.
-
Multicancer blood test moves closer to FDA approval
A blood test designed to detect signals from more than 50 types of cancer before symptoms appear could be on its way to FDA approval, after an advisory panel of experts issued a favourable recommendation.
-
Elfcare to integrate health data with ChatGPT – leaves sharing to users
Healthcare company Elfcare has launched a new connector that allows users to share results from its health assessments with AI assistants. Speaking to Life Science Focus’s sister publication Medtech Magazine, co-founder Julia Elf discusses the initiative and how the company approaches questions around data protection and responsibility.
-
Danish BioInnovation Institute sets sights on Europe
Great science is not enough to build successful companies. As BioInnovation Institute looks beyond Denmark, CEO Jens Nielsen sees access to the right capital as one of the biggest obstacles facing Europe’s research-based startups.
-
Another round of job cuts at BMS headquarters
Bristol Myers Squibb is issuing a new round of layoffs, bringing the total number of jobs cut in its home state of New Jersey to more than 700 so far this year.
-
Novartis makes a move in red‑hot radiopharma space
Novartis is expanding its radiopharmaceutical pipeline through a licensing agreement with Chinese BoomRay Therapeutics worth up to 900 million dollars.
-
Sweden takes half of Nordic spots among world’s top healthtech companies
Ten Nordic companies have made it onto TIME’s list of the World’s Top HealthTech Companies 2026, and half of them are Swedish. Denmark accounts for three, while Norway and Iceland each have one company on the list.
-
AstraZeneca receives EU approval for asthma treatment
AstraZeneca has received approval of its asthma treatment Trixeo Aerosphere in the EU.
-
Private clinic delivers Sweden’s first Leqembi treatment
The Alzheimer drug Leqembi is now available at a private clinic in Stockholm – for those prepared to pay hundreds of thousands of Swedish kronor. On Tuesday, the first patient was treated.
-
Pharmaceutical giants warn: Europe is losing investment
The chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche and Sanofi warn in an open letter that Europe is rapidly losing competitiveness in pharmaceuticals.
-
Health economist after TLV’s assessment: Kisunla still has a chance
Despite several uncertainties, TLV’s assessment of the Alzheimer drug Kisunla offers some hope that the treatment may eventually reach Swedish healthcare. That is the view of Linus Jönsson, professor of health economics at Karolinska Institutet. “It’s not completely hopeless,” he says.
-
Disruptive sells former Guard platform – deal ‘not financially material’
What was formerly Guard Therapeutics became Disruptive Pharma following a reverse acquisition. Now, one of the remaining parts of the former Guard business is being sold as the listed company shifts its full focus to Disruptive’s formulation technology.
-
TLV on Kisunla: High cost, high uncertainty
High treatment costs and considerable uncertainty regarding the durability of the treatment effect. That is TLV’s overall verdict on Eli Lilly’s Alzheimer therapy Kisunla.
-
Intuitive's da Vinci 5 receives CE marking for cardiac surgery
The medical technology company Intuitive's da Vinci 5 surgical system has received CE marking for cardiac surgery in adults in Europe.
-
Changing jobs in the Nordics? Avoid this common mistake
It is easy to assume that working in Copenhagen, Stockholm, Oslo or Helsinki will not be all that different from working in a neighbouring Nordic country. According to career coach Tina Persson, that assumption is one of the biggest pitfalls.
-
Petter Hartman: “Who dares to be the first customer for innovation?”
Sweden invests heavily in research and innovation, but new solutions often hit a wall when it comes to reaching the healthcare system. Unless the public sector is willing to become the first customer, both Swedish companies and patients risk losing out, Petter Hartman writes in this column.
-
Trump calls for major change to childhood vaccines
US President Donald Trump wants some childhood vaccines to be split into five separate doses. He claims the change could reduce autism rates, despite extensive research finding no causal link between vaccines and autism.
-
Billion‑dollar merger forms a radiopharmaceutical heavyweight
Australian Telix Pharmaceuticals is acquiring Germany’s ITM in a deal worth up to USD 2.35 billion.
BREAKING